Virbac SA (ENXTPA: VIRP)
Health Care · Pharmaceuticals · FR
€315.50
-0.79% today · -0.8% 1Y
Virbac SA (ENXTPA: VIRP) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.96B and employs 6,442 people.
Over the last twelve months the share price has lost 0.8%, trading between 297.00 and 389.50.
Tweenvest scores Virbac SA across four factors: quality 82/100, value 86/100, growth 64/100, dividend 36/100. Its strongest factor is value.
VIRP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.96B
- Revenue (TTM)
- $1.71B
- P/E
- 16.98
- EPS
- 18.58
- Dividend yield
- 0.46%
- Beta (5Y)
- 0.79
- 52-week high
- €389.50
- 52-week low
- €297.00
- Avg volume (3M)
- —
- Shares outstanding
- 8.38M
- Employees
- 6,442
- Next earnings
- —
About Virbac SA
Founded in 1968 and based in Carros, France, Virbac S.A. is a prominent developer and distributor of a wide array of animal health products and services. The company's global operations extend across France, Europe, Latin America, North America, Asia Pacific, the Middle East, and Africa, catering to both domestic companion animals and commercial livestock. Its extensive portfolio encompasses vaccines, dental hygiene products, reproductive health solutions, dermatological treatments, parasiticides, diagnostic instruments, antibiotics, and aquaculture offerings. Furthermore, Virbac supplies specialized veterinary pharmaceuticals for anesthesia, geriatric care, behavioral management, and injectable micronutrients, alongside pet food and electronic identification systems. These diverse solutions are designed to support veterinarians, agricultural producers, and individual pet owners worldwide.
- ISIN
- FR0000031577
- Founded
- 1968
- Listed since
- Jul 7, 1992
- Exchange
- Euronext Paris
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Guangdong Zhongsheng Pharmaceutical Co., Ltd.SZSE: 002317 | $3.04B | CN¥24.03 | +2.91% |
| Jilin Aodong Pharmaceutical Group Co., Ltd.SZSE: 000623 | $3.04B | CN¥17.41 | -0.40% |
| Chengdu Kanghong Pharmaceutical Group Co., LtdSZSE: 002773 | $2.99B | CN¥21.80 | +6.76% |
| Enliven Therapeutics, Inc.NasdaqGS: ELVN | $2.98B | $40.63 | -1.76% |
| Neuland Laboratories LimitedBSE: 524558 | $2.86B | Rs21,496.30 | -1.86% |
| MBX Biosciences, Inc.NasdaqGS: MBX | $2.82B | $53.25 | -8.99% |
| Rubicon Research LimitedNSEI: RUBICON | $2.80B | Rs1,630.90 | -2.71% |
| Harbin Pharmaceutical Group Co., Ltd.SHSE: 600664 | $2.78B | CN¥7.40 | -9.09% |
Figures last refreshed Oct 4, 2026.